Experienced, tenacious, and always trial-ready, we are committed to understanding complex legal challenges that impact the future of our clients’ businesses, globally.
Focusing on antitrust, intellectual property, and high-stakes litigation, our extensive teams in the U.S. possess deep knowledge and client-side experience across a range of sectors, including technology, healthcare, life sciences, and consumer products.
With a strong culture of diversity, equity, and inclusion, we build relationships with our clients and colleagues alike, helping communities and acting with purpose. Our client service, entrepreneurialism, and inquisitive nature sit at the heart of the firm, enabling us to prioritize client goals and achieve successful outcomes.
The FTC's record-setting $12 million settlement with Edwards Lifesciences and Genesis MedTech raises critical questions about deal structuring and Hart-Scott-Rodino Act compliance. When does strategic transaction design cross the line into intentional avoidance of premerger notification requirements? Leading antitrust practitioners examine the implications of this landmark enforcement action for deal teams navigating transactions near HSR thresholds.
Jeny M. Maier’s articles from Axinn are most popular:
within Antitrust/Competition Law topic(s)
with readers working within the Business & Consumer Services and Construction & Engineering industries
For nearly 50 years, the Hart-Scott-Rodino Act has given antitrust enforcers a chance to review deals above a certain value before they can close. What happens when the government concludes a transaction was structured intentionally to slip past that review entirely?
Managing partner Jeny Maier and Lexi Michaud of Fried Frank speak with Evan Miller of Vinson & Elkins about HSR Act avoidance and the FTC’s record-setting $12 million settlement with Edwards Lifesciences and Genesis MedTech over Edwards Lifesciences’s acquisition of JC Medical from Genesis. They discuss how the JC Medical deal was valued and structured, how the parties’ failure to file played a role in the FTC’s separate challenge to Edwards’s contemporaneous JenaValve acquisition, what deal teams should consider when assessing a transaction close to the HSR threshold, what the settlement signals about the FTC’s current approach to premerger notification enforcement, and more.
The content of this article is intended to provide a general guide
to the subject matter. Specialist advice should be sought about your
specific circumstances.
